Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (Nature, (2022), 611, 7934, (155-160), 10.1038/s41586-022-05368-8)

Abstract

In the version of this article initially published, the surname of author Michael T. Tetzlaff was misspelled as ‘Tezlaff.’ In addition, the Acknowledgements section omitted mention of grant P50CA221703 from the National Cancer Institute of the National Institutes of Health, which supported the work. The errors have been corrected in the HTML and PDF versions of the article.